Emergent BioSolutions Stock Forecast, Price & News

Emergent BioSolutions (NYSE:EBS) Frequently Asked Questions

Is Emergent BioSolutions a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Emergent BioSolutions stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares.
View analyst ratings for Emergent BioSolutions or view top-rated stocks.

How has Emergent BioSolutions' stock price been impacted by Coronavirus (COVID-19)?

Emergent BioSolutions' stock was trading at $53.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EBS stock has decreased by 22.1% and is now trading at $41.31.
View which stocks have been most impacted by COVID-19.

Are investors shorting Emergent BioSolutions?

Emergent BioSolutions saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 1,620,000 shares, a decline of 47.1% from the October 31st total of 3,060,000 shares. Based on an average daily volume of 630,700 shares, the short-interest ratio is presently 2.6 days. Approximately 3.3% of the shares of the company are short sold.
View Emergent BioSolutions' Short Interest.

When is Emergent BioSolutions' next earnings date?

Emergent BioSolutions is scheduled to release its next quarterly earnings announcement on Thursday, February 17th 2022.
View our earnings forecast for Emergent BioSolutions.

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) issued its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $2.35 by $2.71. The biopharmaceutical company earned $329 million during the quarter, compared to analyst estimates of $484.77 million. Emergent BioSolutions had a net margin of 13.74% and a trailing twelve-month return on equity of 18.63%. The company's quarterly revenue was down 14.6% on a year-over-year basis. During the same period in the previous year, the business posted $2.19 earnings per share.
View Emergent BioSolutions' earnings history.

What guidance has Emergent BioSolutions issued on next quarter's earnings?

Emergent BioSolutions issued an update on its FY 2021 earnings guidance on Thursday, December, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.70 billion-$1.80 billion, compared to the consensus revenue estimate of $1.80 billion.

What price target have analysts set for EBS?

5 brokers have issued 12 month target prices for Emergent BioSolutions' shares. Their forecasts range from $64.00 to $120.00. On average, they expect Emergent BioSolutions' share price to reach $92.25 in the next twelve months. This suggests a possible upside of 123.3% from the stock's current price.
View analysts' price targets for Emergent BioSolutions or view top-rated stocks among Wall Street analysts.

Who are Emergent BioSolutions' key executives?

Emergent BioSolutions' management team includes the following people:

• Robert G. Kramer, President, Chief Executive Officer & Director
• Adam Robert Havey, Chief Operating Officer & Executive Vice President
• Richard Scott Lindahl, Chief Financial Officer, Treasurer & Executive VP
• Sharon M. Solomon, Chief Information Officer & Senior Vice President
• Karen L. Smith, Chief Medical Officer

What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?

38 employees have rated Emergent BioSolutions CEO Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among Emergent BioSolutions' employees.

Who are some of Emergent BioSolutions' key competitors?

Some companies that are related to Emergent BioSolutions include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Exact Sciences (EXAS), Repligen (RGEN), Novavax (NVAX), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of EBS's competitors.

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), salesforce.com (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Square (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

What is Emergent BioSolutions' stock symbol?

Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Who are Emergent BioSolutions' major shareholders?

Emergent BioSolutions' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.85%), Neuberger Berman Group LLC (6.15%), Janus Henderson Group PLC (5.33%), The Manufacturers Life Insurance Company (2.60%), Dimensional Fund Advisors LP (1.83%) and Geode Capital Management LLC (1.53%). Company insiders that own Emergent BioSolutions stock include Adam Havey, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Richard S Lindahl, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi.
View institutional ownership trends for Emergent BioSolutions.

Which major investors are selling Emergent BioSolutions stock?

EBS stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Two Sigma Advisers LP, Morgan Stanley, Neuberger Berman Group LLC, Franklin Resources Inc., Citigroup Inc., FourThought Financial LLC, and Rice Hall James & Associates LLC. Company insiders that have sold Emergent BioSolutions company stock in the last year include Kathryn C Zoon, Robert Kramer, and Sue Bailey.
View insider buying and selling activity for Emergent BioSolutions or view top insider-selling stocks.

Which major investors are buying Emergent BioSolutions stock?

EBS stock was purchased by a variety of institutional investors in the last quarter, including Hotchkis & Wiley Capital Management LLC, Nordea Investment Management AB, Hillcrest Asset Management LLC, Bank of New York Mellon Corp, Retirement Systems of Alabama, UBS Group AG, Goldman Sachs Group Inc., and The Manufacturers Life Insurance Company .
View insider buying and selling activity for Emergent BioSolutions or or view top insider-buying stocks.

How do I buy shares of Emergent BioSolutions?

Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Emergent BioSolutions' stock price today?

One share of EBS stock can currently be purchased for approximately $41.31.

How much money does Emergent BioSolutions make?

Emergent BioSolutions has a market capitalization of $2.22 billion and generates $1.56 billion in revenue each year. The biopharmaceutical company earns $305.10 million in net income (profit) each year or $4.20 on an earnings per share basis.

How many employees does Emergent BioSolutions have?

Emergent BioSolutions employs 2,200 workers across the globe.

What is Emergent BioSolutions' official website?

The official website for Emergent BioSolutions is www.emergentbiosolutions.com.

Where are Emergent BioSolutions' headquarters?

Emergent BioSolutions is headquartered at 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879.

How can I contact Emergent BioSolutions?

Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at (240) 631-3200, via email at [email protected], or via fax at 301-795-1899.